Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04924569 · ClinicalTrials.gov registry record
Continence Care Registry
A clinical trial of Neurogenic Bladder and Non-Neurogenic Bladder, sponsored by Hollister Incorporated.
- Active
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT04924569: Active study of Neurogenic Bladder and Non-Neurogenic Bladder, sponsored by Hollister Incorporated.
NCT04924569 is a study of Neurogenic Bladder and Non-Neurogenic Bladder that is active but no longer recruiting, run by Hollister Incorporated. The registered enrollment target is 600 participants, above the 55-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (991% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04924569, a study of Neurogenic Bladder and Non-Neurogenic Bladder, is active but no longer recruiting, sponsored by Hollister Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational research study aims to build a multinational electronic patient-reported outcomes (ePRO) registry of adult end users in outpatient and community settings using intermittent catheter(s) to void via the urethra to manage urinary retention and incomplete bladder emptying. Research participants will be asked to self-report on various attributes of their currently prescribed intermittent catheters and other various aspects of using an intermittent catheter.
Primary Outcome
To build a longitudinal continence care ePRO-based, direct-to-consumer registry addressing overall intermittent self-catheterization product satisfaction, QoL, healthcare resource utilization associated with urinary symptoms, urinary tract infections and other complications including burden of ISC over time, and end-user product preference factors.
Conditions Studied
Study Locations (1)
Illinois
- Hollister Incorporated - Libertyville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2026-05 |
What the registry record for NCT04924569 still lists
NCT04924569 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 55-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (991% higher).
The record links to 2 conditions, with Neurogenic Bladder appearing as the primary indexed condition, and to 0 interventions.
NCT04924569 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04924569 about?
NCT04924569 is a clinical study titled "Continence Care Registry". This observational research study aims to build a multinational electronic patient-reported outcomes (ePRO) registry of adult end users in outpatient and community settings using intermittent catheter(s) to void via the urethra to manage urinary retention and incomplete bladder emptying. Research pa...
What is the current status of trial NCT04924569?
This trial is currently active not recruiting. The enrollment target is 600 participants. The study started on 2021-05-24. Estimated completion is 2026-05.
What conditions does trial NCT04924569 study?
This clinical trial studies the following conditions: Neurogenic Bladder, Non-Neurogenic Bladder.
Who is sponsoring clinical trial NCT04924569?
This trial is sponsored by Hollister Incorporated, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04924569 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurogenic Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04924569's enrollment target sits among peer trials
600 1st of 16 higher than 16 of 16 other Neurogenic Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurogenic Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation
RECRUITING · Early Phase 1
-
Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms
RECRUITING
-
Intravesical LGG VS Saline Bladder Wash RCT
RECRUITING · Phase 2
-
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
RECRUITING · NA
-
Vascularized Composite Bladder Allograft Transplantation
RECRUITING · NA
-
Concomitant Renal and Urinary Bladder Allograft Transplantation
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI